查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1496701

进行性遗传性肝内胆汁淤积治疗市场：按药物类型、分销管道和最终用户划分 - 全球预测 2024-2030

Progressive Familial Intrahepatic Cholestasis Treatment Market by Drug Type (Cholestyramine, Rifampicin, Ursodeoxycholic Acid), Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies), End-Users - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

进行性遗传性肝内胆汁淤积治疗市场规模预估至2023年为1.1352亿美元，2024年达到1.1862亿美元，2030年达到1.5614亿美元，复合年增长率预估为4.65%。

进行性遗传性肝内胆汁淤积（PFIC）是一组罕见的遗传性肝损伤，由胆道上皮转运蛋白缺陷引起，导致胆汁形成和流动受损，进行性肝臟疾病。如果不及时治疗，该疾病的严重程度和进展可能会导致肝功能衰竭。治疗策略旨在控制症状、改善肝功能并防止进一步损害。医疗保健专业人员和公众对 PFIC 的认识不断提高，可以实现更快、更准确的诊断。先进的基因检测和分子诊断在识别受影响个体方面发挥着重要作用，从而可以进行早期干预。 FDA 和 EMA 等监管机构认识到对罕见疾病（包括 PFIC）进行标靶治疗的必要性。这导致了加快审查流程、津贴计划和其他针对罕见疾病特异性治疗方法开发的奖励。 PFIC的治疗在技术上是透过新疗法或肝臟移植，但价格昂贵。这可能会对患者、家庭和医疗保健系统造成沉重负担，并限制获得所需治疗的机会。新疗法和肝臟移植的高昂费用可能对患者、家庭和医疗保健系统造成沉重负担，限制了获得所需治疗的机会。该领域的研究和开发带来了创新的治疗方法，包括新药物和改进的手术技术。这正在扩大治疗策略组合併创造市场成长机会。

主要市场统计
基准年[2023] 11352万美元
预测年份 [2024] 11862万美元
预测年份 [2030] 1.5614亿美元
复合年增长率（%） 4.65%

区域洞察

成熟的医疗基础设施和不断上涨的医疗成本正在支持美洲 PFIC 治疗市场的成长。此外，由患者支持组织和政府支持的针对罕见疾病的健康措施在该地区非常活跃，提高了意识和诊断率。包括孤儿药指定在内的监管激励措施鼓励製药公司投资研发，从而形成强大的治疗产品线。由于对罕见疾病治疗的认识提高和医疗设施的改善，加拿大和南美国家的市场不断增长。亚太地区的 PFIC 治疗市场呈现出多样化的景象，日本和澳洲等国家在医疗保健创新和治疗取得方面处于领先地位。这些国家对 PFIC 及其治疗方案的认识相对较高，并得到强大的医疗保健系统和支持罕见疾病管理的政策的支持。在有利的监管政策、发达的医疗保健系统和高认知度的推动下，欧洲已成为 PFIC 研究和治疗的主导地区。欧洲药品管理局 (EMA) 在快速核准治疗罕见疾病（包括 PFIC）的药物方面发挥关键作用。该地区针对罕见疾病采取的统一方法（以跨境医疗保健措施为代表）使 PFIC 患者受益匪浅。中东和非洲拥有先进的医疗保健系统，开始认识并解决 PFIC。

FPNV定位矩阵

FPNV 定位矩阵对于评估进行性遗传性肝内胆汁淤积治疗市场中供应商的定位至关重要。此矩阵提供了对供应商的全面评估，并检验了与业务策略和产品满意度相关的关键指标。这种详细的评估使用户能够根据自己的要求做出明智的决定。根据评估结果，供应商被分为代表其成功程度的四个像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市场占有率分析

市场占有率分析是一种综合工具，可以对进行性遗传性肝内胆汁淤积治疗市场中供应商的现状进行深入而详细的评估。透过仔细比较和分析供应商的贡献，您可以更深入地了解每个供应商的绩效以及他们在争夺市场占有率时面临的挑战。这些贡献包括整体收益、客户群和其他关键指标。此外，该分析还提供了对该行业竞争性质的宝贵见解，包括在研究基准年期间观察到的累积、分散主导地位和合併特征等因素。有了这些详细信息，供应商可以做出更明智的决策并製定有效的策略，以在市场竞争中保持领先地位。

策略分析与建议

策略分析对于寻求在全球市场站稳脚跟的组织至关重要。对进行性遗传性肝内胆汁淤积治疗市场当前地位的全面评估将帮助公司做出符合其长期愿望的明智决策。此关键评估涉及对组织的资源、能力和整体绩效进行彻底分析，以确定核心优势和需要改进的领域。

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 改善的医疗基础设施增加了对进行性遗传性肝内胆汁淤积症的检测
      • 扩大患者权益团体的角色以扩大 PFIC 治疗
    • 抑制因素
      • 获得 PFIC 治疗和费用负担问题
    • 机会
      • PFIC 研究和诊断技术的进展
      • 政府对 PFIC 治疗的有利核准
    • 任务
      • PFIC 疾病管理和治疗效果的复杂性
  • 市场区隔分析
    • 药物类型：增加考来烯胺的使用以降低肝臟和血液中胆汁酸的浓度
    • 通路：首选网路药局，可持续且方便地取得处方药。
    • 最终使用者：PFIC 治疗可能在医院进行，以处理 PFIC 的严重併发症
  • 市场趋势分析
    • 美洲对 PFIC 治疗的监管核准增加
    • 政府对罕见疾病治疗方法进展的积极支持，并加强推动亚太地区的医疗保健服务和解决方案。
    • 增加研究活动，探索有效的治疗方法和标准，并在欧洲、中东和非洲地区建立製药业
  • 高通膨的累积效应
  • 波特五力分析
  • 价值炼和关键路径分析
  • 法规结构分析

第六章进行性遗传性肝内胆汁淤积治疗市场：依药物类型

  • 消胆胺
  • 利福平
  • 熊去氧胆酸

第七章进行性遗传性肝内胆汁淤积治疗市场：依通路

  • 医院药房
  • 网路药房
  • 零售药房

第八章进行性遗传性肝内胆汁淤积治疗市场：依最终用户

  • 门诊手术中心
  • 医院
  • 专科诊所

第九章北美与南美遗传性肝内胆汁淤积症治疗市场的进行性

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章 亚太地区遗传性肝内胆汁淤积症治疗市场的进行性

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章欧洲、中东和非洲进行性遗传性肝内胆汁淤积治疗市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 市场占有率分析（2023）
  • FPNV定位矩阵（2023）
  • 竞争情境分析
    • FDA核准Livmarli 用于治疗进行性遗传性肝内胆汁淤积症患者的搔痒症
    • 加拿大政府将拨款 2,000 万加元，用于改善患有罕见疾病（包括进行性遗传性肝内胆汁淤积症）的儿童的健康状况。
    • 法国政府向 Vivet Therapeutics 授予 490 万欧元津贴，用于创新基因疗法的开发
    • 加拿大卫生署核准Bylvay (odevixibat) 治疗 PFIC 相关搔痒
    • 北康成药 CAN108 NDA 获 NMPA核准
    • UKRI 投入 1400 万英镑进一步研究进行进行性遗传性肝内胆汁淤积症和其他罕见疾病
    • Jadeite Medicines 在日本透过 3 期试验和孤儿药资格认定推进 PFIC 的治疗
    • 印度已拨款40亿卢比加强罕见疾病治疗，并专注于加强PFIC和患者照护。
    • Ipsen 透过策略收购 Albireo Pharma 加强罕见疾病药物供应

第13章竞争产品组合

  • 主要企业简介
  • 主要产品系列
Product Code: MRR-AD517FAAA5F2

[187 Pages Report] The Progressive Familial Intrahepatic Cholestasis Treatment Market size was estimated at USD 113.52 million in 2023 and expected to reach USD 118.62 million in 2024, at a CAGR 4.65% to reach USD 156.14 million by 2030.

Progressive familial intrahepatic cholestasis (PFIC) is a group of rare genetic liver disorders that occur due to defects in the biliary epithelial transporters, leading to impaired bile formation and flow and resulting in progressive liver disease. The severity and progression of the disease lead to liver failure if left untreated. Treatment strategies aim to manage symptoms, improve liver function, and prevent further damage. A growing awareness of PFIC among healthcare professionals and the public leads to earlier and more accurate diagnoses. Advanced genetic testing and molecular diagnostics have played a crucial role in identifying affected individuals, allowing for earlier intervention. Regulatory bodies such as the FDA and EMA have recognized the need for treatments targeting rare diseases, including PFIC. This has led to expedited review processes, grant programs, and other incentives for the development of therapies specifically aimed at rare conditions. The treatment of PFIC, precisely with novel therapies and liver transplantation, can be costly. This significantly burdens patients, families, and healthcare systems, potentially limiting access to necessary treatments. The high cost of treatment with novel therapies and liver transplantation poses a significant burden on patients, families, and healthcare systems, potentially limiting access to necessary treatments. Research and development in the field have led to innovative treatment options, including new pharmaceutical drugs and improved surgical techniques. This has expanded the treatment strategy portfolio, creating market growth opportunities.

KEY MARKET STATISTICS
Base Year [2023] USD 113.52 million
Estimated Year [2024] USD 118.62 million
Forecast Year [2030] USD 156.14 million
CAGR (%) 4.65%

Regional Insights

The well-established healthcare infrastructure and increased healthcare expenditure support the growth of the PFIC treatment market in the Americas. Furthermore, the region benefits from active patient advocacy groups and government-supported health initiatives aimed at rare diseases, enhancing awareness and diagnosis rates. Regulatory incentives, including orphan drug designation, encourage pharmaceutical companies to invest in research and development, leading to a robust pipeline of therapeutic drugs. Canada and South American countries represent a growing market with increasing awareness and improving healthcare facilities for the treatment of rare diseases. The APAC region presents a diverse landscape for the PFIC treatment market, with countries including Japan and Australia leading in healthcare innovation and access to treatments. These countries have relatively high awareness of PFIC and its treatment options, supported by strong healthcare systems and policies favoring rare disease management. Europe is a leading region in terms of PFIC research and treatment, driven by favorable regulatory policies, extensive healthcare systems, and high levels of awareness. The European Medicines Agency (EMA) plays a crucial role in the fast-tracking approval of drugs for rare diseases, including PFIC. The region's unified approach to tackling rare diseases, exemplified by cross-border healthcare initiatives, significantly benefits PFIC patients. The Middle East and Africa, with advanced healthcare systems, have begun to recognize and address PFIC.

Market Insights

  • Market Dynamics

The market dynamics represent an ever-changing landscape of the Progressive Familial Intrahepatic Cholestasis Treatment Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

    • Market Drivers
      • Increasing detection of progressive familial intrahepatic cholestasis with improvements in healthcare infrastructure
      • Expanding role of patient advocacy groups to expand PFIC treatments
    • Market Restraints
      • Access and affordability issues of PFIC treatments
    • Market Opportunities
      • Advancements in PFIC research and diagnostic technologies
      • Favorable government approvals for PFIC treatments
    • Market Challenges
      • Complexity in PFIC disease management and treatment efficacy
  • Market Segmentation Analysis
    • Drug Type: Rising usage of cholestyramine for reducing the level of bile acids in the liver and blood
    • Distribution Channel: Preference for online pharmacies for continuous and convenient access to prescribed medications.
    • End-Users: High potential for PFIC treatments in hospitals to manage severe complications of PFIC
  • Market Disruption Analysis
  • Porter's Five Forces Analysis
  • Value Chain & Critical Path Analysis
  • Pricing Analysis
  • Technology Analysis
  • Patent Analysis
  • Trade Analysis
  • Regulatory Framework Analysis

FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Progressive Familial Intrahepatic Cholestasis Treatment Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Progressive Familial Intrahepatic Cholestasis Treatment Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments

FDA Endorses Livmarli for Pruritus Management in Progressive Familial Intrahepatic Cholestasis Patients

The U.S. Food and Drug Administration (FDA) has officially approved Mirum Pharmaceuticals' Livmarli oral solution in a significant advancement for patients with Progressive Familial Intrahepatic Cholestasis (PFIC), aimed at treating cholestatic pruritus in individuals aged five years and above. This decision is supported by extensive research efforts and a compelling accumulation of clinical data, demonstrating notable progress in several key health indicators, particularly in alleviating pruritus among affected children. [Published On: 2024-03-14]

Canadian Government Allocates CAD 20 Million to Enhance Health Outcomes for Children with Rare Diseases, Including Progressive Familial Intrahepatic Cholestasis

The Canadian government allocates an investment of CAD 20 million aimed at improving health outcomes. This funding initiative is part of a comprehensive strategy to address the challenges faced by children living with rare conditions, such as progressive familial intrahepatic cholestasis (PFIC), by enhancing access to specialized care, supporting innovative research, and fostering the development of new treatments. This investment highlights the government's commitment to elevating the standard of care for vulnerable populations, ensuring that children with rare diseases can look forward to a brighter, healthier future. [Published On: 2024-02-28]

French Government Awards Euro 4.9 Million Grant for Innovative Gene Therapy Development by Vivet Therapeutics"

The French Government, through its France Health Innovation Plan 2023, allocated a Euro 4.9 million (USD 5.3 million) grant to Vivet Therapeutics. This Paris-based biotech firm spearheads the development of VTX-806, a gene therapy aimed at combating cerebrotendinous xanthomatosis (CTX), the buildup of cholesterol in nerve cells. This initiative falls within the broader strategic framework of accelerating Biotherapies and Bioproduction in innovative therapies. [Published On: 2024-02-01]

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Progressive Familial Intrahepatic Cholestasis Treatment Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the Progressive Familial Intrahepatic Cholestasis Treatment Market, highlighting leading vendors and their innovative profiles. These include AbbVie, Inc., Calliditas Therapeutics AB, CANbridge Pharmaceuticals Inc., Centurion Laboratories Private Limited, CymaBay Therapeutics, Inc., Enomark, Glenmark Pharmaceuticals Limited, Healthy Life Pharma Pvt. Ltd., Hebei Xingang Pharmaceutical Co., Ltd., Intercept Pharmaceuticals, Inc., Ipsen Pharma, Jackson Laboratories Pvt Ltd., Macleods Pharmaceuticals Ltd., Mirum Pharmaceuticals, Inc., Novartis AG, Par Pharmaceuticals, Inc. by Endo International PLC, Pfizer Inc., Sanofi S.A., SiNi Pharma Pvt. Ltd., Taj Pharmaceuticals Limited, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Viatris Inc., Vivet Therapeutics, Wellona Pharma, and Zoic Biotech Pvt. Ltd..

Market Segmentation & Coverage

This research report categorizes the Progressive Familial Intrahepatic Cholestasis Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Drug Type
    • Cholestyramine
    • Rifampicin
    • Ursodeoxycholic Acid
  • Distribution Channel
    • Hospital Pharmacies
    • Online Pharmacies
    • Retail Pharmacies
  • End-Users
    • Ambulatory Surgical Centers
    • Hospitals
    • Specialty Clinics
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing detection of progressive familial intrahepatic cholestasis with improvements in healthcare infrastructure
      • 5.1.1.2. Expanding role of patient advocacy groups to expand PFIC treatments
    • 5.1.2. Restraints
      • 5.1.2.1. Access and affordability issues of PFIC treatments
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancements in PFIC research and diagnostic technologies
      • 5.1.3.2. Favorable government approvals for PFIC treatments
    • 5.1.4. Challenges
      • 5.1.4.1. Complexity in PFIC disease management and treatment efficacy
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Drug Type: Rising usage of cholestyramine for reducing the level of bile acids in the liver and blood
    • 5.2.2. Distribution Channel: Preference for online pharmacies for continuous and convenient access to prescribed medications.
    • 5.2.3. End-Users: High potential for PFIC treatments in hospitals to manage severe complications of PFIC
  • 5.3. Market Trend Analysis
    • 5.3.1. Rising approvals for PFIC treatment from regulatory bodies in the Americas
    • 5.3.2. Favorable government support for advancing therapeutics for rare diseases and growing efforts to advance medical and healthcare services and solutions in the APAC region.
    • 5.3.3. Increasing research activities to explore effective treatments and standards and the well-established pharmaceutical industry of the EMEA region
  • 5.4. Cumulative Impact of High Inflation
  • 5.5. Porter's Five Forces Analysis
    • 5.5.1. Threat of New Entrants
    • 5.5.2. Threat of Substitutes
    • 5.5.3. Bargaining Power of Customers
    • 5.5.4. Bargaining Power of Suppliers
    • 5.5.5. Industry Rivalry
  • 5.6. Value Chain & Critical Path Analysis
  • 5.7. Regulatory Framework Analysis

6. Progressive Familial Intrahepatic Cholestasis Treatment Market, by Drug Type

  • 6.1. Introduction
  • 6.2. Cholestyramine
  • 6.3. Rifampicin
  • 6.4. Ursodeoxycholic Acid

7. Progressive Familial Intrahepatic Cholestasis Treatment Market, by Distribution Channel

  • 7.1. Introduction
  • 7.2. Hospital Pharmacies
  • 7.3. Online Pharmacies
  • 7.4. Retail Pharmacies

8. Progressive Familial Intrahepatic Cholestasis Treatment Market, by End-Users

  • 8.1. Introduction
  • 8.2. Ambulatory Surgical Centers
  • 8.3. Hospitals
  • 8.4. Specialty Clinics

9. Americas Progressive Familial Intrahepatic Cholestasis Treatment Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Progressive Familial Intrahepatic Cholestasis Treatment Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Progressive Familial Intrahepatic Cholestasis Treatment Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. FDA Endorses Livmarli for Pruritus Management in Progressive Familial Intrahepatic Cholestasis Patients
    • 12.3.2. Canadian Government Allocates CAD 20 Million to Enhance Health Outcomes for Children with Rare Diseases, Including Progressive Familial Intrahepatic Cholestasis
    • 12.3.3. French Government Awards Euro 4.9 Million Grant for Innovative Gene Therapy Development by Vivet Therapeutics"
    • 12.3.4. Approval of Bylvay (odevixibat) by Health Canada for PFIC-Related Pruritus
    • 12.3.5. CANbridge Pharmaceuticals Gains NMPA Approval for CAN108 NDA
    • 12.3.6. UKRI Allocates GBP 14 Million to Advance Research on Progressive Familial Intrahepatic Cholestasis and Other Rare Diseases
    • 12.3.7. Jadeite Medicines Advances Treatment for PFIC with Phase 3 Trial and Orphan Drug Designation in Japan
    • 12.3.8. India Boosts Rare Diseases Treatment, Allocates INR 40 Crore with a Focus on PFIC and Enhanced Patient Care
    • 12.3.9. Ipsen Enhances Rare Disease Offerings with Strategic Acquisition of Albireo Pharma

13. Competitive Portfolio

  • 13.1. Key Company Profiles
  • 13.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, 2018-2030 (USD THOUSAND)
  • FIGURE 4. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD THOUSAND)
  • FIGURE 6. PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET DYNAMICS
  • FIGURE 7. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD THOUSAND)
  • FIGURE 9. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD THOUSAND)
  • FIGURE 11. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2023 VS 2024 VS 2030 (USD THOUSAND)
  • FIGURE 13. AMERICAS PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 14. AMERICAS PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD THOUSAND)
  • FIGURE 15. UNITED STATES PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 16. UNITED STATES PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD THOUSAND)
  • FIGURE 17. ASIA-PACIFIC PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. ASIA-PACIFIC PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD THOUSAND)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD THOUSAND)
  • FIGURE 21. PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 22. PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, 2018-2023 (USD THOUSAND)
  • TABLE 4. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, 2024-2030 (USD THOUSAND)
  • TABLE 5. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY REGION, 2018-2023 (USD THOUSAND)
  • TABLE 6. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY REGION, 2024-2030 (USD THOUSAND)
  • TABLE 7. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD THOUSAND)
  • TABLE 8. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD THOUSAND)
  • TABLE 9. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY CHOLESTYRAMINE, BY REGION, 2018-2023 (USD THOUSAND)
  • TABLE 10. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY CHOLESTYRAMINE, BY REGION, 2024-2030 (USD THOUSAND)
  • TABLE 11. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY RIFAMPICIN, BY REGION, 2018-2023 (USD THOUSAND)
  • TABLE 12. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY RIFAMPICIN, BY REGION, 2024-2030 (USD THOUSAND)
  • TABLE 13. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY URSODEOXYCHOLIC ACID, BY REGION, 2018-2023 (USD THOUSAND)
  • TABLE 14. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY URSODEOXYCHOLIC ACID, BY REGION, 2024-2030 (USD THOUSAND)
  • TABLE 15. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD THOUSAND)
  • TABLE 16. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD THOUSAND)
  • TABLE 17. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2023 (USD THOUSAND)
  • TABLE 18. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2024-2030 (USD THOUSAND)
  • TABLE 19. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2023 (USD THOUSAND)
  • TABLE 20. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2024-2030 (USD THOUSAND)
  • TABLE 21. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2023 (USD THOUSAND)
  • TABLE 22. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2024-2030 (USD THOUSAND)
  • TABLE 23. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD THOUSAND)
  • TABLE 24. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD THOUSAND)
  • TABLE 25. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2023 (USD THOUSAND)
  • TABLE 26. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2024-2030 (USD THOUSAND)
  • TABLE 27. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2023 (USD THOUSAND)
  • TABLE 28. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2024-2030 (USD THOUSAND)
  • TABLE 29. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2023 (USD THOUSAND)
  • TABLE 30. GLOBAL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2024-2030 (USD THOUSAND)
  • TABLE 31. AMERICAS PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD THOUSAND)
  • TABLE 32. AMERICAS PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD THOUSAND)
  • TABLE 33. AMERICAS PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD THOUSAND)
  • TABLE 34. AMERICAS PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD THOUSAND)
  • TABLE 35. AMERICAS PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD THOUSAND)
  • TABLE 36. AMERICAS PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD THOUSAND)
  • TABLE 37. AMERICAS PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2023 (USD THOUSAND)
  • TABLE 38. AMERICAS PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY COUNTRY, 2024-2030 (USD THOUSAND)
  • TABLE 39. ARGENTINA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD THOUSAND)
  • TABLE 40. ARGENTINA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD THOUSAND)
  • TABLE 41. ARGENTINA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD THOUSAND)
  • TABLE 42. ARGENTINA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD THOUSAND)
  • TABLE 43. ARGENTINA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD THOUSAND)
  • TABLE 44. ARGENTINA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD THOUSAND)
  • TABLE 45. BRAZIL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD THOUSAND)
  • TABLE 46. BRAZIL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD THOUSAND)
  • TABLE 47. BRAZIL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD THOUSAND)
  • TABLE 48. BRAZIL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD THOUSAND)
  • TABLE 49. BRAZIL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD THOUSAND)
  • TABLE 50. BRAZIL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD THOUSAND)
  • TABLE 51. CANADA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD THOUSAND)
  • TABLE 52. CANADA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD THOUSAND)
  • TABLE 53. CANADA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD THOUSAND)
  • TABLE 54. CANADA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD THOUSAND)
  • TABLE 55. CANADA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD THOUSAND)
  • TABLE 56. CANADA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD THOUSAND)
  • TABLE 57. MEXICO PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD THOUSAND)
  • TABLE 58. MEXICO PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD THOUSAND)
  • TABLE 59. MEXICO PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD THOUSAND)
  • TABLE 60. MEXICO PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD THOUSAND)
  • TABLE 61. MEXICO PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD THOUSAND)
  • TABLE 62. MEXICO PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD THOUSAND)
  • TABLE 63. UNITED STATES PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD THOUSAND)
  • TABLE 64. UNITED STATES PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD THOUSAND)
  • TABLE 65. UNITED STATES PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD THOUSAND)
  • TABLE 66. UNITED STATES PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD THOUSAND)
  • TABLE 67. UNITED STATES PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD THOUSAND)
  • TABLE 68. UNITED STATES PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD THOUSAND)
  • TABLE 69. UNITED STATES PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY STATE, 2018-2023 (USD THOUSAND)
  • TABLE 70. UNITED STATES PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY STATE, 2024-2030 (USD THOUSAND)
  • TABLE 71. ASIA-PACIFIC PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD THOUSAND)
  • TABLE 72. ASIA-PACIFIC PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD THOUSAND)
  • TABLE 73. ASIA-PACIFIC PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD THOUSAND)
  • TABLE 74. ASIA-PACIFIC PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD THOUSAND)
  • TABLE 75. ASIA-PACIFIC PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD THOUSAND)
  • TABLE 76. ASIA-PACIFIC PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD THOUSAND)
  • TABLE 77. ASIA-PACIFIC PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2023 (USD THOUSAND)
  • TABLE 78. ASIA-PACIFIC PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY COUNTRY, 2024-2030 (USD THOUSAND)
  • TABLE 79. AUSTRALIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD THOUSAND)
  • TABLE 80. AUSTRALIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD THOUSAND)
  • TABLE 81. AUSTRALIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD THOUSAND)
  • TABLE 82. AUSTRALIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD THOUSAND)
  • TABLE 83. AUSTRALIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD THOUSAND)
  • TABLE 84. AUSTRALIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD THOUSAND)
  • TABLE 85. CHINA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD THOUSAND)
  • TABLE 86. CHINA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD THOUSAND)
  • TABLE 87. CHINA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD THOUSAND)
  • TABLE 88. CHINA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD THOUSAND)
  • TABLE 89. CHINA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD THOUSAND)
  • TABLE 90. CHINA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD THOUSAND)
  • TABLE 91. INDIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD THOUSAND)
  • TABLE 92. INDIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD THOUSAND)
  • TABLE 93. INDIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD THOUSAND)
  • TABLE 94. INDIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD THOUSAND)
  • TABLE 95. INDIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD THOUSAND)
  • TABLE 96. INDIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD THOUSAND)
  • TABLE 97. INDONESIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD THOUSAND)
  • TABLE 98. INDONESIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD THOUSAND)
  • TABLE 99. INDONESIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD THOUSAND)
  • TABLE 100. INDONESIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD THOUSAND)
  • TABLE 101. INDONESIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD THOUSAND)
  • TABLE 102. INDONESIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD THOUSAND)
  • TABLE 103. JAPAN PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD THOUSAND)
  • TABLE 104. JAPAN PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD THOUSAND)
  • TABLE 105. JAPAN PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD THOUSAND)
  • TABLE 106. JAPAN PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD THOUSAND)
  • TABLE 107. JAPAN PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD THOUSAND)
  • TABLE 108. JAPAN PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD THOUSAND)
  • TABLE 109. MALAYSIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD THOUSAND)
  • TABLE 110. MALAYSIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD THOUSAND)
  • TABLE 111. MALAYSIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD THOUSAND)
  • TABLE 112. MALAYSIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD THOUSAND)
  • TABLE 113. MALAYSIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD THOUSAND)
  • TABLE 114. MALAYSIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD THOUSAND)
  • TABLE 115. PHILIPPINES PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD THOUSAND)
  • TABLE 116. PHILIPPINES PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD THOUSAND)
  • TABLE 117. PHILIPPINES PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD THOUSAND)
  • TABLE 118. PHILIPPINES PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD THOUSAND)
  • TABLE 119. PHILIPPINES PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD THOUSAND)
  • TABLE 120. PHILIPPINES PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD THOUSAND)
  • TABLE 121. SINGAPORE PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD THOUSAND)
  • TABLE 122. SINGAPORE PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD THOUSAND)
  • TABLE 123. SINGAPORE PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD THOUSAND)
  • TABLE 124. SINGAPORE PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD THOUSAND)
  • TABLE 125. SINGAPORE PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD THOUSAND)
  • TABLE 126. SINGAPORE PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD THOUSAND)
  • TABLE 127. SOUTH KOREA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD THOUSAND)
  • TABLE 128. SOUTH KOREA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD THOUSAND)
  • TABLE 129. SOUTH KOREA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD THOUSAND)
  • TABLE 130. SOUTH KOREA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD THOUSAND)
  • TABLE 131. SOUTH KOREA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD THOUSAND)
  • TABLE 132. SOUTH KOREA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD THOUSAND)
  • TABLE 133. TAIWAN PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD THOUSAND)
  • TABLE 134. TAIWAN PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD THOUSAND)
  • TABLE 135. TAIWAN PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD THOUSAND)
  • TABLE 136. TAIWAN PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD THOUSAND)
  • TABLE 137. TAIWAN PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD THOUSAND)
  • TABLE 138. TAIWAN PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD THOUSAND)
  • TABLE 139. THAILAND PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD THOUSAND)
  • TABLE 140. THAILAND PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD THOUSAND)
  • TABLE 141. THAILAND PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD THOUSAND)
  • TABLE 142. THAILAND PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD THOUSAND)
  • TABLE 143. THAILAND PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD THOUSAND)
  • TABLE 144. THAILAND PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD THOUSAND)
  • TABLE 145. VIETNAM PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD THOUSAND)
  • TABLE 146. VIETNAM PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD THOUSAND)
  • TABLE 147. VIETNAM PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD THOUSAND)
  • TABLE 148. VIETNAM PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD THOUSAND)
  • TABLE 149. VIETNAM PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD THOUSAND)
  • TABLE 150. VIETNAM PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD THOUSAND)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD THOUSAND)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD THOUSAND)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD THOUSAND)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD THOUSAND)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD THOUSAND)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD THOUSAND)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2023 (USD THOUSAND)
  • TABLE 158. EUROPE, MIDDLE EAST & AFRICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY COUNTRY, 2024-2030 (USD THOUSAND)
  • TABLE 159. DENMARK PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD THOUSAND)
  • TABLE 160. DENMARK PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD THOUSAND)
  • TABLE 161. DENMARK PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD THOUSAND)
  • TABLE 162. DENMARK PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD THOUSAND)
  • TABLE 163. DENMARK PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD THOUSAND)
  • TABLE 164. DENMARK PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD THOUSAND)
  • TABLE 165. EGYPT PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD THOUSAND)
  • TABLE 166. EGYPT PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD THOUSAND)
  • TABLE 167. EGYPT PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD THOUSAND)
  • TABLE 168. EGYPT PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD THOUSAND)
  • TABLE 169. EGYPT PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD THOUSAND)
  • TABLE 170. EGYPT PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD THOUSAND)
  • TABLE 171. FINLAND PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD THOUSAND)
  • TABLE 172. FINLAND PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD THOUSAND)
  • TABLE 173. FINLAND PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD THOUSAND)
  • TABLE 174. FINLAND PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD THOUSAND)
  • TABLE 175. FINLAND PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD THOUSAND)
  • TABLE 176. FINLAND PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD THOUSAND)
  • TABLE 177. FRANCE PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD THOUSAND)
  • TABLE 178. FRANCE PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD THOUSAND)
  • TABLE 179. FRANCE PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD THOUSAND)
  • TABLE 180. FRANCE PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD THOUSAND)
  • TABLE 181. FRANCE PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD THOUSAND)
  • TABLE 182. FRANCE PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD THOUSAND)
  • TABLE 183. GERMANY PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD THOUSAND)
  • TABLE 184. GERMANY PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD THOUSAND)
  • TABLE 185. GERMANY PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD THOUSAND)
  • TABLE 186. GERMANY PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD THOUSAND)
  • TABLE 187. GERMANY PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD THOUSAND)
  • TABLE 188. GERMANY PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD THOUSAND)
  • TABLE 189. ISRAEL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD THOUSAND)
  • TABLE 190. ISRAEL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD THOUSAND)
  • TABLE 191. ISRAEL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD THOUSAND)
  • TABLE 192. ISRAEL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD THOUSAND)
  • TABLE 193. ISRAEL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD THOUSAND)
  • TABLE 194. ISRAEL PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD THOUSAND)
  • TABLE 195. ITALY PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD THOUSAND)
  • TABLE 196. ITALY PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD THOUSAND)
  • TABLE 197. ITALY PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD THOUSAND)
  • TABLE 198. ITALY PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD THOUSAND)
  • TABLE 199. ITALY PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD THOUSAND)
  • TABLE 200. ITALY PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD THOUSAND)
  • TABLE 201. NETHERLANDS PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD THOUSAND)
  • TABLE 202. NETHERLANDS PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD THOUSAND)
  • TABLE 203. NETHERLANDS PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD THOUSAND)
  • TABLE 204. NETHERLANDS PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD THOUSAND)
  • TABLE 205. NETHERLANDS PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD THOUSAND)
  • TABLE 206. NETHERLANDS PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD THOUSAND)
  • TABLE 207. NIGERIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD THOUSAND)
  • TABLE 208. NIGERIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD THOUSAND)
  • TABLE 209. NIGERIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD THOUSAND)
  • TABLE 210. NIGERIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD THOUSAND)
  • TABLE 211. NIGERIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD THOUSAND)
  • TABLE 212. NIGERIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD THOUSAND)
  • TABLE 213. NORWAY PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD THOUSAND)
  • TABLE 214. NORWAY PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD THOUSAND)
  • TABLE 215. NORWAY PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD THOUSAND)
  • TABLE 216. NORWAY PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD THOUSAND)
  • TABLE 217. NORWAY PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD THOUSAND)
  • TABLE 218. NORWAY PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD THOUSAND)
  • TABLE 219. POLAND PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD THOUSAND)
  • TABLE 220. POLAND PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD THOUSAND)
  • TABLE 221. POLAND PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD THOUSAND)
  • TABLE 222. POLAND PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD THOUSAND)
  • TABLE 223. POLAND PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD THOUSAND)
  • TABLE 224. POLAND PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD THOUSAND)
  • TABLE 225. QATAR PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD THOUSAND)
  • TABLE 226. QATAR PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD THOUSAND)
  • TABLE 227. QATAR PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD THOUSAND)
  • TABLE 228. QATAR PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD THOUSAND)
  • TABLE 229. QATAR PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD THOUSAND)
  • TABLE 230. QATAR PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD THOUSAND)
  • TABLE 231. RUSSIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD THOUSAND)
  • TABLE 232. RUSSIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD THOUSAND)
  • TABLE 233. RUSSIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD THOUSAND)
  • TABLE 234. RUSSIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD THOUSAND)
  • TABLE 235. RUSSIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD THOUSAND)
  • TABLE 236. RUSSIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD THOUSAND)
  • TABLE 237. SAUDI ARABIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD THOUSAND)
  • TABLE 238. SAUDI ARABIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD THOUSAND)
  • TABLE 239. SAUDI ARABIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD THOUSAND)
  • TABLE 240. SAUDI ARABIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD THOUSAND)
  • TABLE 241. SAUDI ARABIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD THOUSAND)
  • TABLE 242. SAUDI ARABIA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD THOUSAND)
  • TABLE 243. SOUTH AFRICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD THOUSAND)
  • TABLE 244. SOUTH AFRICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD THOUSAND)
  • TABLE 245. SOUTH AFRICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD THOUSAND)
  • TABLE 246. SOUTH AFRICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD THOUSAND)
  • TABLE 247. SOUTH AFRICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2023 (USD THOUSAND)
  • TABLE 248. SOUTH AFRICA PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY END-USERS, 2024-2030 (USD THOUSAND)
  • TABLE 249. SPAIN PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS TREATMENT MARKET SIZE, BY DRUG TYPE,